Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.10
  • 50 Day Moving Average: $1.15
  • 200 Day Moving Average: $1.10
  • 52-Week Range: $82,870,000.00 - $0.51
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.07
  • P/E Growth: 0.00
  • Market Cap: $91.16M
  • Outstanding Shares: 82,870,000
  • Beta: 2.26
Profitability:
  • Return on Equity: -43.03%
  • Return on Assets: -40.38%
Debt:
  • Current Ratio: 22.64%
  • Quick Ratio: 22.64%
Additional Links:
Companies Related to Catalyst Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.25 (195.45% upside)

Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetDetails
10/14/2016Roth CapitalReiterated RatingBuy$2.50View Rating Details
10/5/2016Piper Jaffray CompaniesUpgradeNeutral -> Overweight$4.00View Rating Details
6/14/2016HC WainwrightReiterated RatingBuyView Rating Details
2/20/2016SunTrust Banks, Inc.Reiterated RatingBuy$7.00 -> $6.00View Rating Details
6/24/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.05)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.09)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.07)($0.05)ViewN/AView Earnings Details
5/16/2014Q114($0.06)($0.07)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Current Year EPS Consensus Estimate: $-0.24 EPS
Next Year EPS Consensus Estimate: $-0.27 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.06)($0.06)($0.06)
Q2 20161($0.06)($0.06)($0.06)
Q3 20162($0.06)($0.06)($0.06)
Q4 20162($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 28.13%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
DateHeadline
News IconStock in Focus: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - SKV News (NASDAQ:CPRX)
skvnews.com - February 25 at 2:39 AM
News IconAnalysts Peer Into Their Crystal Balls For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX): Where Is It headed? - Winfield Review (NASDAQ:CPRX)
winfieldreview.com - February 24 at 9:38 PM
News IconCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Files SEC Prospectus - ABN Newswire (press release) (NASDAQ:CPRX)
www.abnnewswire.net - February 24 at 9:38 PM
News IconEye on Technical Levels for Catalyst Pharmaceuticals Inc (CPRX) - The Standard (NASDAQ:CPRX)
6milestandard.com - February 24 at 9:38 PM
News IconAnalysts Are Bullish on These Healthcare Stocks: CPRX, BCLI - Analyst Ratings (NASDAQ:CPRX)
www.analystratings.com - February 22 at 10:39 AM
News IconIs there Upside to Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ? - Rockville Register (NASDAQ:CPRX)
rockvilleregister.com - February 22 at 10:39 AM
News IconWhat is the Sell-side Saying About Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)? - Aiken Advocate (NASDAQ:CPRX)
aikenadvocate.com - February 22 at 10:39 AM
News IconWhat is The Sell-side Recommending on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Fenix Parts, Inc. (NASDAQ ... - Sherwood Daily (NASDAQ:CPRX)
sherwooddaily.com - February 22 at 10:39 AM
News IconStock Watch for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - SKV News (NASDAQ:CPRX)
skvnews.com - February 18 at 10:45 AM
News IconABR Of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock At 1 - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - February 18 at 10:45 AM
News IconBroadfin Capital is Buying Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shares - Small Cap Exclusive (press release) (NASDAQ:CPRX)
smallcapexclusive.com - February 13 at 10:10 PM
News IconCatalyst Pharmaceuticals Announces Participation at SunTrust Robinson Humphrey's 2017 Orphan Drug Day - EconoTimes (NASDAQ:CPRX)
www.econotimes.com - February 9 at 9:56 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Announces Participation at SunTrust Robinson Humphrey’s 2017 Orphan Drug Day (NASDAQ:CPRX)
finance.yahoo.com - February 9 at 4:53 PM
News IconInvestor Center: Technical Watch for Catalyst Pharmaceutical Partners Inc. (CPRX) - Piedmont Register (NASDAQ:CPRX)
piedmontregister.com - February 8 at 9:52 PM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Projected EPS At $-0.07 - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - February 8 at 9:52 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Nelson Research (NASDAQ:CPRX)
nelsonobserver.com - January 31 at 9:59 PM
News IconStock Volatility Review for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - The Tribune (NASDAQ:CPRX)
lakecitytribune.com - January 31 at 9:59 PM
News IconTechnical Investor Update on Shares of Catalyst Pharmaceutical Partners Inc. (CPRX) - Sherwood Daily (NASDAQ:CPRX)
sherwooddaily.com - January 31 at 4:58 PM
News IconTop Stock With Upside & Growth Potential: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 31 at 4:58 PM
News IconZeroing in on Company Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 31 at 4:58 PM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock ABR ... - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - January 27 at 10:52 PM
News IconADX, MA, and RSI in Focus for Catalyst Pharmaceutical Partners Inc. (CPRX) - Sherwood Daily (NASDAQ:CPRX)
sherwooddaily.com - January 27 at 5:52 PM
News IconTaking Aim at Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 27 at 5:52 PM
News IconStock Watch for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - The Tribune (NASDAQ:CPRX)
lakecitytribune.com - January 26 at 10:38 PM
News IconWilliams %R, RSI, and ADX Update for Catalyst Pharmaceutical Partners Inc. (CPRX) - Sherwood Daily (NASDAQ:CPRX)
sherwooddaily.com - January 26 at 5:37 PM
News IconIs This The Right Stock For Heady Investors: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 26 at 5:37 PM
News IconRSI Review on Shares of Catalyst Pharmaceutical Partners Inc. (CPRX) - Sherwood Daily (NASDAQ:CPRX)
sherwooddaily.com - January 26 at 3:44 AM
News IconConsensus Take: Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings & Ratings Watch - Aiken Advocate (NASDAQ:CPRX)
aikenadvocate.com - January 20 at 10:40 PM
News IconCatalyst Pharmaceutical Partners, Inc. (CPRX) Valuation According To Analysts - UK Market News (NASDAQ:CPRX)
www.ukmarketnews.co.uk - January 20 at 10:40 PM
News IconWatching the Technicals on Shares of Catalyst Pharmaceutical Partners Inc. (CPRX) - Sherwood Daily (NASDAQ:CPRX)
sherwooddaily.com - January 20 at 10:40 PM
News IconShort Interest Filing: After Reaching Milestone, Is Catalyst ... - Baxley Report (NASDAQ:CPRX)
baxleyreport.com - January 18 at 9:51 PM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Projected to Achieve EPS Of $-0.07 - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - January 18 at 4:48 PM
News IconKnuckling Down on Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 17 at 10:20 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Wall Street Beacon (NASDAQ:CPRX)
wsbeacon.com - January 17 at 5:17 PM
News IconCatalyst Pharmaceuticals Inc CPRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CPRX)
www.bioportfolio.com - January 16 at 9:29 PM
News IconWill The Needle Move For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CPRX)
wsbeacon.com - January 16 at 4:28 PM
News IconNotable Stock For Under $5: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 16 at 4:28 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Wall Street Beacon (NASDAQ:CPRX)
wsbeacon.com - January 14 at 4:31 PM
News IconStock ABR Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 1 - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - January 14 at 3:14 AM
News IconBargain Hunter Investor Update on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 14 at 3:14 AM
News IconCatalyst Pharmaceuticals, Inc. (CPRX) : How Do the Technicals Stack Up? - The USA Commerce (NASDAQ:CPRX)
theusacommerce.com - January 14 at 3:14 AM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Projected ... - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - January 11 at 9:54 PM
News IconCan This Stock Make a Ripple in the Market: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 11 at 9:54 PM
News IconAre Institutions Jumping Ship on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Wall Street Beacon (NASDAQ:CPRX)
wsbeacon.com - January 11 at 9:54 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 9 at 5:37 PM
News IconPrimed for Breakout or Bust? A look at Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 9 at 5:37 PM
seekingalpha.com logoCatalyst Pharmaceuticals: Why This $1 Biotech Stock Is A Strong Buy For 2017 (NASDAQ:CPRX)
seekingalpha.com - January 4 at 5:31 PM
News IconAre There Catalysts to Propel This Stock Forward: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Prospect Journal (NASDAQ:CPRX)
prospectjournal.com - January 3 at 12:48 PM
News IconStock ABR Of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 1 - Stock Observer (NASDAQ:CPRX)
www.thestockobserver.com - December 31 at 2:55 AM
investornewswire.com logoSentiments And Ratings Alert: Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Investor Newswire (NASDAQ:CPRX)
www.investornewswire.com - December 30 at 2:56 AM

Social

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued 12 month price targets for Catalyst Pharmaceuticals' stock. Their forecasts range from $2.50 to $4.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $3.25 in the next year.

When will Catalyst Pharmaceuticals announce their earnings?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (9.90%) and Kingdon Capital Management L.L.C. (0.91%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, David D Muth, Donald A Denkhaus, M Douglas Winship, Patrick J Mcenany, Philip H Coelho and Steve Miller.

Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C.. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, David D Muth, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller.

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Catalyst Pharmaceuticals stock cost?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $1.10.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Earnings History Chart

Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Dividend History Chart

Dividend Payments by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Last Updated on 2/27/2017 by MarketBeat.com Staff